Kyle Lowry recently passed the 10,000 point mark in a Raptors uniform and deserves to be honoured with a statue outside Scotiabank Arena in Toronto. The question is, which one of Kyle's iconic poses should be immortalized?
Kyle Lowry recently passed the 10,000 point mark in a Raptors uniform and deserves to be honoured with a statue outside Scotiabank Arena in Toronto. The question is, which one of Kyle's iconic poses should be immortalized?
The actor responded to a viral tweet about how her song from the original "Pitch Perfect" movie forced a summer camp to ban empty cups.
The one-tonne robot wiggles its wheels before rolling forwards across Jezero Crater's dusty terrain.
Italy reported 297 coronavirus-related deaths on Friday against 339 the day before, the health ministry said, while the daily tally of new infections rose to 24,036 from 22,865 the day before. Some 378,463 tests for COVID-19 were carried out in the past day, compared with a previous 339,635, the health ministry said. Italy has registered 99,271 deaths linked to COVID-19 since its outbreak emerged in February last year, the second-highest toll in Europe after Britain and the seventh-highest in the world.
The high-end accelerometer market witnessed supply chain difficulties in the initial phase of the COVID-19 pandemic. The demand from some industries was also down during the first half of 2020. Industries like automotive and manufacturing were significantly affected.New York, March 05, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "High-end Accelerometer Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" - https://www.reportlinker.com/p06030481/?utm_source=GNW However, the COVID-19 pandemic has also expanded the scope of MEMS sensors, like high end accelerometers, for many new applications.- The increasing adoption of MEMS technology has also played a significant role in expanding the application base for high-end accelerometers by scaling down the size and power consumption of these devices, without compromising on the performance metrics.- High-end accelerometers are also being increasingly used in navigation systems for high-speed trains and autonomous vehicles. These devices are widely used for performing shock and vibrational test for evaluating the performance of automobiles in duress.- High-end accelerometers for automotive applications possess a bias stability range more significant than that of industrial grade applications, and the working range is dependent on the intended end-applications. For instance, the working range could be as high as 40g for crash avoidance systems.- The increased vibration levels of automated machinery in high-end industrial applications during high-speed operations, such as cutting or milling, are expected to damage critical materials and reduce precision. Such cases require higher stability to have higher machine control. Thus, high-end accelerometers are being adopted significantly for these applications.Key Market TrendsNavigational Applications to Hold a Major Share- High sensitivity accelerometers are crucial for the next generation navigation and guidance systems, including tight coupling to existing GPS engines, pressure sensors, and platform stabilization for space applications.- The incentive for a MEMS-based inertial accelerometer for navigational applications is based upon the hopes of realizing a small, low cost, lightweight, and highly-sensitive alternative to existing macro-scale approaches. The successful fabrication of a low cost, high-sensitivity MEMS accelerometer results in new applications for both consumer and military users that aren’t feasible with current technologies.- For instance, personal handheld navigators for military and consumer applications, as well as GPS-denied navigation applications, such as in valleys, urban areas, and within buildings and caves, utilize high-end accelerometers.- Recently, in September 2019, Sensonor, a designer and manufacturer of advanced MEMS sensor solutions, announced the launch of its latest inertial IMU – the STIM318 IMU. A high-accuracy tactical-grade IMU, the new solution is designed to offer increased accelerometer performance to support demanding guidance and navigation applications within the defense and commercial markets. Furthermore, the STIM318 can deliver additional capability to applications already using the STIM300 (Sensonor’s IMU) and many other applications by competitively replacing the fiber-optic gyros (FOGs).North America to Account for the Largest Share- The North American region is witnessing growth in the development of new high-performance accelerometers, as companies in the region are investing toward introducing advanced and innovative accelerometers. The increased spending by the US defense department to acquire high performance equipment is the major factor driving growth of high-end accelerometers in the country.- The United States has the world’s largest defense budget. With this rise, the country also focusses on precision guided munitions (PGMs), such as laser-guided bombs and cruise missiles, that have become the weapons of choice for the US military, providing a high degree of accuracy, while avoiding widespread collateral damage. These applications demand high performance, compact form factor, ruggedized accelerometers to improve tactical IMUs for long-duration guidance without GPS.- The US military uses a navigation-grade inertial measurement unit developed by Northrop Grumman. This miniaturized unit is based on MEMS technology to enable navigation by sensing acceleration and angular motion, and providing data outputs used by vehicle control systems for guidance.Competitive LandscapeThe high-end accelerometer market consists of some major players, and in terms of market share, few of the major players currently dominate the market. These major players with prominent share in the market are focusing on expanding their customer base across foreign countries. These companies are leveraging on strategic collaborative initiatives to increase their market share and increase their profitability.- December 2020 - TDK Corporation introduced the InvenSense IAM-20680HP high-performance automotive monolithic 6-axis MotionTracking sensor platform for non-safety relevant automotive applications, which includes the IAM-20680HP IMU MEMS sensor and the DK-20680HP developer kit. InvenSense’s IAM-20680HP combines a 3-axis gyroscope and a 3-axis accelerometer in a thin 3 x 3 x 0.75mm (16-pin LGA) package and is automotive qualified based on AEC-Q100 Grade 2.Reasons to Purchase this report:- The market estimate (ME) sheet in Excel format- 3 months of analyst supportRead the full report: https://www.reportlinker.com/p06030481/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: firstname.lastname@example.org US: (339)-368-6001 Intl: +1 339-368-6001
A Russian court on Friday ordered jailed dissident Alexei Navalny to pay 500,000 roubles ($6,700) in damages in a lawsuit filed by Yevgeny Prigozhin, a Kremlin-linked businessman, the court said. Navalny, a prominent critic of President Vladimir Putin, was jailed for two and a half years last month over alleged parole violations related to an embezzlement case he said was trumped up for political reasons, something the authorities deny. Prigozhin's company, Konkord, said the court told Navalny to pay damages for comments he made that were deemed defamatory, inaccurate and offensive.
We'll take one in every colour.
Emma-Jayne Magson was originally convicted of murder and jailed for a minimum of 17 years at Leicester Crown Court in November 2016.
AM Best will participate in the opening discussion at the 2021 Virtual Reinsurance & ESSL Symposium taking place online for two days beginning March 11, 2021.
Police investigate major incident in Wales with 'number of casualties'Officers and paramedics attend scene in village of Ynyswen, Rhondda Cynon Taf South Wales police said the incident happened at about noon on Friday. Composite: The Guardian Design Team
OTTAWA — The Supreme Court of Canada says two men convicted of terrorism offences received a fair trial even though the judge made errors in assembling the jury. The top court explained its reasoning today for ruling last October there would be no new trial for Raed Jaser and Chiheb Esseghaier. The men were found guilty in 2015 of terror-related charges arising mainly from an alleged al-Qaida-inspired plot to derail a passenger train travelling between the United States and Canada. They appealed their convictions, with counsel for Jaser and a court-appointed lawyer for Esseghaier arguing the jury at the trial was improperly constituted. In August 2019, the Ontario Court of Appeal ordered a fresh trial for the men on grounds the jury was indeed chosen incorrectly. The Crown successfully argued in a Supreme Court hearing last fall the convictions should not be overturned on the basis of an error in the jury-selection process that did not deny the men fair trial rights. This report by The Canadian Press was first published March 5, 2021. The Canadian Press
TORONTO — Losses in the technology sector led Canada's main stock index lower in late-morning trading despite strength in energy stocks as the price of oil marched higher. The S&P/TSX composite index was down 92.43 points at 18,033.29. In New York, the Dow Jones industrial average was down 75.41 points at 30,848.73. The S&P 500 index was down 24.92 points at 3,743.55, while the Nasdaq composite was down 232.39 points at 12,491.08. The Canadian dollar traded for 78.85 cents US compared with 79.13 cents US on Thursday. The April crude oil contract was up US$1.73 at US$65.56 per barrel and the April natural gas contract was down five cents at US$2.70 per mmBTU. The April gold contract was down US$7.20 at US$1,693.50 an ounce and the May copper contract was up 10 cents at US$4.07 a pound. This report by The Canadian Press was first published March 5, 2021. Companies in this story: (TSX:GSPTSE, TSX:CADUSD=X) The Canadian Press
WAKEFIELD, Mass., March 05, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today reports that eight sites are now participating in the Company’s international Phase 2 clinical trial assessing Brilacidin as a novel therapeutic in hospitalized patients with COVID-19. The trial is now posted on clinicaltrials.gov (https://clinicaltrials.gov/ct2/show/NCT04784897), which shows seven sites as recruiting and enrolling patients. An eighth site is also now enrolling in addition, and the Company has informed clinicaltrials.gov of the change in status. Fifteen patients have already been dosed in the trial. More sites are coming online, which is expected to further accelerate enrollment and treatment. The trial doesn’t exclude any variants of SARS-CoV-2, the virus responsible for COVID-19. Virulent coronavirus strains have scoured different countries around the world recently, including highly contagious versions, such as P1 and B.1.1.7. Brazil this week reported that COVID -19 daily deaths reached a new high due to P1. According to Russian news agency Tass, nearly 1,500 coronavirus mutations have been discovered in Russia, a country where seven sites are currently enrolling patients in the Company’s COVID-19 clinical trial. The Company is interested to see what information, if any, might be gleaned from the trial regarding variants considering laboratory studies have indicated Brilacidin to have strong pan-coronavirus treatment potential, remaining unaffected by viral mutations. “We are pleased to see patient recruitment and enrollment in our Brilacidin for COVID-19 clinical trial ramping up,” said Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “COVID-19 is making a resurgence worldwide, with cases up 9 percent last week in Europe and cases no longer decreasing in the United States. Emerging variants are likely partially to blame for this rise. With its unique three-in-one therapeutic profile—antiviral, anti-inflammatory and antibacterial—we believe Brilacidin can play an important role in treating COVID-19. A broad-spectrum therapeutic that can be shown to inhibit coronaviruses would be a valuable countermeasure in fighting coronavirus disease and other viral outbreaks, now and in the future.” Brilacidin COVID-19 Clinical Trial The Phase 2 clinical trial is a randomized, double-blind, placebo-controlled, international, multi-center study with planned enrollment of ~120 subjects with moderate-to-severe COVID-19. Two treatment arms are enrolling patients—active and placebo, with ~60 patients per arm. The trial’s primary endpoint is time to sustained recovery through Day 29, using a clinical status ordinal scale based on that used in the series of National Institute of Allergy and Infectious Diseases (NIAID) Adaptive COVID-19 Treatment Trials (ACTTs). Additional endpoints include: in-hospital outcomes, all-cause mortality, measurement of disease biomarkers and inflammation-related biomarkers, changes to SARS-CoV-2 viral load, and other key measures. Brilacidin and COVID-19 Brilacidin, which has received FDA Fast Track designation for the potential treatment of COVID-19, is one of the few drugs targeting COVID-19 that has been tested in human trials (a total of 8) for other clinical indications, providing established safety and efficacy data on over 460 subjects, thereby potentially enabling it to rapidly help address the novel coronavirus crisis. Pre-clinical testing at independent laboratories supports Brilacidin’s antiviral ability to safely and potently inhibit SARS-CoV-2, and multiple strains of human coronaviruses (H-CoVs). In a human lung cell line against SARS-CoV-2, Brilacidin achieved a Selectivity Index of 426. A molecular screening study of 11,552 compounds also supports Brilacidin as a promising novel coronavirus treatment. Brilacidin antiviral research to date has been limited to laboratory-based experiments. Additional pre-clinical and clinical data support Brilacidin’s inhibition of IL-6, IL-1β, TNF-α and other pro-inflammatory cytokines and chemokines, which have been identified as central drivers in the worsening prognoses of hospitalized COVID-19 patients. Brilacidin’s robust antimicrobial properties might also help to fight secondary bacterial infections, which can co-present in up to 20 percent of COVID-19 patients. Collectively, these data support Brilacidin as a unique 3-in-1 combination—antiviral, immuno/anti-inflammatory, and antimicrobial—COVID-19 therapeutic candidate, with pan-coronavirus treatment potential. The Company has initiated a randomized, placebo-controlled Phase 2 clinical trial of Brilacidin for treatment of COVID-19 in moderate-to-severe hospitalized patients. A peer-reviewed article in Viruses supporting Brilacidin’s COVID-19 treatment potential can be accessed at the link below. Bakovic, A.; Risner, K.; Bhalla, N. (et al). Brilacidin Demonstrates Inhibition of SARS-CoV-2 in Cell Culture. Viruses 2021, 13, 271; https://doi.org/10.3390/v13020271https://www.mdpi.com/1999-4915/13/2/271 Global COVID-19 Cases and Mortality An online tool tracking COVID-19 cases and mortality, both in the U.S. and globally, can be found on the Company’s website (http://www.ipharminc.com), and at the following link:https://ipixcovid19tracker.com/ Alerts Sign-up for Innovation Pharmaceuticals email alerts is available at: http://www.ipharminc.com/email-alerts/ About Innovation Pharmaceuticals Innovation Pharmaceuticals Inc. (IPIX) is a clinical stage biopharmaceutical company developing a world-class portfolio of innovative therapies addressing multiple areas of unmet medical need, including inflammatory diseases, cancer, infectious diseases, and dermatologic diseases. Brilacidin, a versatile compound with broad therapeutic potential, is in a new chemical class called defensin-mimetics. A Phase 2 trial of Brilacidin as an oral rinse for the prevention of Severe Oral Mucositis (SOM) in patients with Head and Neck Cancer met its primary and secondary endpoints, including reducing the incidence of SOM. The Company plans to advance Brilacidin oral rinse into Phase 3 development, subject to available financial resources. Positive results were also observed in a Phase 2 Proof-of-Concept trial treating patients locally with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS). Brilacidin for UP/UPS was licensed to Alfasigma S.p.A. in July 2019, who have recently completed a Phase 1 study with their formulation. A Phase 2b trial of Brilacidin showed a single intravenous dose of the drug delivered comparable outcomes to a seven-day dosing regimen of the FDA-approved blockbuster daptomycin in treating Acute Bacterial Skin and Skin Structure Infection. Brilacidin, based on promising in vitro antiviral activity against SARS-CoV-2, is being evaluated in a Phase 2 clinical trial as a potential treatment for COVID-19. Kevetrin is a novel anti-cancer drug shown to modulate p53, often referred to as the “Guardian Angel Gene” due to its crucial role in controlling cell mutations and has successfully completed a Phase 2 trial in Ovarian Cancer. More information is available on the Company website at www.IPharmInc.com. Forward-Looking Statements: This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 including statements concerning future drug development plans, statements regarding the antiviral capabilities and therapeutic potential of Brilacidin and its impact on SARS-CoV-2 (COVID-19) and other coronaviruses, as well as government regulatory approvals to continue clinical testing. Other statements regarding future product developments, and markets, including with respect to specific indications, and any other statements which are other than statements of historical fact. These statements involve risks but not limited to risks related to conducting pre-clinical studies and clinical trials and seeking regulatory and licensing approvals for Brilacidin and Kevetrin in the US and other jurisdictions; that prior test results may not be replicated in future studies and trials, uncertainties and assumptions that could cause the Company’s actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. The Company has in some cases identified forward-looking statements by using words such as “anticipates,” “believes,” “hopes,” “estimates,” “looks,” “expects,” “plans,” “intends,” “goal,” “potential,” “may,” “suggest,” and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are the Company’s need for, and the availability of, substantial capital in the future to fund its operations and research and development; including the amount and timing of the sale of shares of common stock under securities purchase agreements; the fact that the Company’s licensee(s) may not successfully complete pre-clinical or clinical testing and the Company will not receive milestone payments, or the fact that the Company’s compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in the Company’s filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. The Company undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation. INVESTOR AND MEDIA CONTACTS Innovation Pharmaceuticals Inc. Leo Ehrlich email@example.com
March 17, 2021, TrackVia hosts Forrester analyst John Bratincevic and PMI and Stearns Lending leaders in discussing the citizen developer movement
Health Canada has authorized the Johnson & Johnson COVID-19 vaccine, produced by Janssen Inc., the first single-dose vaccine approved for use in Canada.
High-flying growth stocks like Shopify Inc. could continue to drop at the hands of the tech stock market crash, but you still shouldn't panic. The post Start of a Stock Market Crash? Probably Not. Here’s What Beginner Investors Should Do appeared first on The Motley Fool Canada.
Carmakers attempting to navigate their way through a shortage of microchips while mitigating the effects of a global pandemic might have a new problem to worry about. The severe winter storms that left thousands without power and water in Texas in February 2021 also shut down the refineries that provide the raw materials in seat foam. Getting to the root of the problem requires following a surprisingly long supply chain.
The "Methylamine nitrate (CAS 22113-87-7) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.
LOS ANGELES, March 05, 2021 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming April 20, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation ("HSAC", "Immunovant", or the “Company”) (NASDAQ: IMVT) securities between October 2, 2019 and February 1, 2021, inclusive (the “Class Period”). If you suffered a loss on your Immunovant investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/immunovant-inc/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at firstname.lastname@example.org to learn more about your rights. On September 29, 2019, HSAC entered into an agreement with Immunovant Sciences Ltd. (“Legacy Immunovant”) to effect a merger between the two entities (the “Merger”). Immunovant is developing IMVT-1401, a novel fully human monoclonal antibody, which is Phase IIa clinical trials for the treatment of myasthenia gravis (“MG”) and thyroid eye disease (“TED”). The Company has also completed initiation of Phase II clinical trials of IMVT-1401 for the treatment of warm autoimmune hemolytic anemia (“WAIHA”). On February 2, 2021, the Company issued a press release “announc[ing] a voluntary pause of dosing in its ongoing clinical trials for IMVT-1401.” The Company also disclosed that it “has become aware of a physiological signal consisting of elevated total cholesterol and LDL [low-density lipoproteins] levels in IMVT-1401-treated patients” and “[o]ut of an abundance of caution, the Company has decided to voluntarily pause dosing in ongoing clinical studies in both TED and in [WAIHA], in order to inform patients, investigators, and regulators as well as to modify the monitoring program.” On this news, the Company’s stock price fell $18.22 per share, or 42.08%, to close at $25.08 per share on February 2, 2021, thereby injuring investors. The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) HSAC had performed inadequate due diligence into Legacy Immunovant prior to the Merger, and/or ignored or failed to disclose safety issues associated with IMVT-1401; (2) IMVT-1401 was less safe than the Company had led investors to believe, particularly with respect to treating TED and WAIHA; (3) the foregoing foreseeably diminished IMVT-1401's prospects for regulatory approval, commercial viability, and profitability; and (4) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. Follow us for updates on LinkedIn, Twitter, or Facebook. If you purchased or otherwise acquired Immunovant securities during the Class Period, you may move the Court no later than April 20, 2021 to request appointment as lead plaintiff in this putative class action lawsuit. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to email@example.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Contacts Glancy Prongay & Murray LLP, Los Angeles Charles Linehan, 310-201-9150 or 888-773-9224 firstname.lastname@example.org www.glancylaw.com
Shareholders with $10,000 losses or more are encouraged to contact the firmLOS ANGELES, March 05, 2021 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming April 19, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired EHang Holdings Limited (“EHang” or the “Company”) (NASDAQ: EH) American Depositary Shares (“ADSs”) between December 12, 2019 and February 16, 2021, inclusive (the “Class Period”). If you suffered a loss on your EHang investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/ehang-holdings-limited/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at email@example.com to learn more about your rights. On February 16, 2021, analyst Wolfpack Research published a research report entitled “EHang: A Stock Promotion Destined to Crash and Burn.” Citing “extensive evidence” including “behind-the-scenes photographs, recorded phone calls, and videos of on-site visits to EH’s various facilities,” the report alleged that EHang is “an elaborate stock promotion, built on largely fabricated revenues based on sham sales contracts with a customer [Shanghai Kunxiang Intelligent Technology Co., Ltd.] who appears to us to be more interested in helping inflate the value of its investment in EH . . . than about buying its products.” Wolfpack Research also noted that “in just 14 months as a publicly traded company, EH’s PR team has put out 50 press releases . . . . However, EH’s constant stream of press releases are easily proven untrue.” Finally, the report alleged that Wolfpack Research “obtained Chinese court records which show that EH’s ADRs may already be in serious jeopardy due to legal issues in China.” On this news, the Company’s share price fell $77.79, or approximately 62.7%, to close at $46.30 per share, thereby injuring investors. The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the Company’s purported regulatory approvals in Europe and North America for its EH216 were for use as a drone, and not for carrying passengers; (2) its relationship with its purported primary customer is a sham; (3) EHang has only collected on a fraction of its reported sales since its ADS began trading on NASDAQ in December 2019; (4) the Company’s manufacturing facilities were practically empty and lacked evidence of advanced manufacturing equipment or employees; and (5) as a result, Defendants’ statements about its business, operations, and prospects were materially false and misleading and/or lacked reasonable basis at all relevant times. Follow us for updates on LinkedIn, Twitter, or Facebook. If you purchased or otherwise acquired EHang ADSs during the Class Period, you may move the Court no later than April 19, 2021 to request appointment as lead plaintiff in this putative class action lawsuit. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to firstname.lastname@example.org, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Contacts Glancy Prongay & Murray LLP, Los Angeles Charles Linehan, 310-201-9150 or 888-773-9224 email@example.com www.glancylaw.com
COPENHAGEN, Denmark – March 5, 2021 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) will announce its 2020 annual report on Friday, March 12, 2021. The management of Bavarian Nordic will host a conference call at 2:00 pm CET (8:00 am EST) on the same day to present the full-year results followed by a Q&A session. A live and replay version of the call and relevant slides will be available at http://bit.ly/3rkKNed. To join the Q&A session dial one of the following numbers and state the participant code 5589045: Denmark: +45 32 72 80 42, UK: +44 (0) 844 571 8892, USA: +1 631-510-7495. About Bavarian Nordic Bavarian Nordic is a fully integrated vaccines company focused on the development, manufacture and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and have been a long-term supplier to the U.S. Strategic National Stockpile of a non-replicating smallpox vaccine, which has been approved by the FDA under the trade name JYNNEOS®, also for the protection against monkeypox. The vaccine is approved as a smallpox vaccine in Europe under the trade name IMVANEX® and in Canada under the trade name IMVAMUNE®. Our commercial product portfolio furthermore contains the market-leading vaccine Rabipur®/RabAvert® against rabies and Encepur® against tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including an Ebola vaccine, MVABEA®, which is licensed to Janssen. For more information visit www.bavarian-nordic.com. Contacts Europe: Rolf Sass Sørensen, Vice President Investor Relations & Communications. Tel: +45 61 77 47 43 U.S.: Graham Morrell, Paddock Circle Advisors (US), Tel: +1 781 686 9600